Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isatuximab + belantamab mafodotin + dexamethasone
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Isatuximab + belantamab mafodotin + dexamethasone is a combination regimen evaluated for the treatment of relapsed or refractory multiple myeloma (RRMM). Isatuximab is a monoclonal antibody targeting CD38, leading to antitumor activity through immune-mediated mechanisms. Belantamab mafodotin is an antibody-drug conjugate targeting B-cell maturation antigen (BCMA); it delivers a cytotoxic agent (MMAF) to multiple myeloma cells, resulting in apoptosis. Dexamethasone is a corticosteroid used to augment anti-myeloma effects and reduce inflammation. This triplet aims to exploit complementary mechanisms—immune modulation, targeted cytotoxin delivery, and anti-inflammatory/pro-apoptotic effects—to improve efficacy in refractory or heavily pretreated myeloma patients[7][1].
- Other names
- isatuximab + belantamab mafodotin + dexamethasone
02
Targets
CD38 (Cluster of Differentiation 38)GR (Glucocorticoid receptor)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on isatuximab + belantamab mafodotin + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isatuximab + belantamab mafodotin + dexamethasone.